 Beta-adrenergic-antagonist drugs prevention gastrointestinal bleeding patients cirrhosis esophageal varices analysis data prognostic factors patients randomized clinical trials Franco-Italian Multicenter Study Group BACKGROUND value beta-adrenergic-antagonist drug therapy prevention initial episodes gastrointestinal bleeding patients cirrhosis esophageal varices uncertain positive negative study results METHODS study data individual patients randomized trials efficacy treatment patients beta-adrenergic-antagonist drug propranolol nadolol placebo RESULTS years mean SE percentage patients upper gastrointestinal bleeding percent beta-adrenergic-antagonist treatment group percent control group percentage patients fatal bleeding percent treatment group percent control group percentage patients years percent treatment group percent control group age severity cirrhosis account survival rate treatment group percentage patients bleeding years percent treatment group percent control group propranolol first episode Severe cirrhosis presence ascites bleeding death groups efficacy beta-adrenergic-antagonist therapy prevention bleeding fatal bleeding prevention death adjustment cause severity cirrhosis ascites size varices CONCLUSIONS Propranolol nadolol effective first bleeding mortality rate gastrointestinal bleeding patients cirrhosis severity